Search

Author/Creator Friedman, Gary S.

1. Efficacy of Tofacitinib in Patients With Ulcerative Colitis by Prior Tumor Necrosis Factor Inhibitor Treatment Status: Results From OCTAVE Induction and Maintenance Studies: 640. (October 2017)

Authors:
Dubinsky, Marla C.; Peyrin‐Biroulet, Laurent; Melmed, Gil Y.; Hou, Jason K.; Woodworth, Deborah A.; Friedman, Gary S.; Zhang, Haiying; Maller, Eric; Quirk, Daniel; Nduaka, Chudy I.; Su, Chinyu
Journal:
American journal of gastroenterology
Issue:
Volume 112(2017)Supplement 1
Page Start:
Record Type:
Journal Article
View Content:
Available online (eLD content is only available in our Reading Rooms) ↗

2. Integrated Safety Analyses of Tofacitinib in Ulcerative Colitis Clinical Trials: 731. (October 2017)

Authors:
Sandborn, William J.; Panés, Julian; D'Haens, Geert; Sands, Bruce E.; Su, Chinyu; Moscariello, Michele; Jones, Thomas V.; Pedersen, Ronald D.; Friedman, Gary S.; Lawendy, Nervin; Chan, Gary
Journal:
American journal of gastroenterology
Issue:
Volume 112(2017)Supplement 1
Page Start:
Record Type:
Journal Article
View Content:
Available online (eLD content is only available in our Reading Rooms) ↗

3. Pregnancy Outcomes in the Tofacitinib Ulcerative Colitis OCTAVE Studies: 740. (October 2017)

Authors:
Mahadevan, Uma; Baumgart, Daniel C.; Dubinsky, Marla C.; Lawendy, Nervin; Friedman, Gary S.; Konijeti, Gauree G.; Gröchenig, Hans P.; Jones, Thomas V.; Marren, Amy; Thorpe, Andrew J.; Nduaka, Chudy I.; Su, Chinyu
Journal:
American journal of gastroenterology
Issue:
Volume 112(2017)Supplement 1
Page Start:
Record Type:
Journal Article
View Content:
Available online (eLD content is only available in our Reading Rooms) ↗

4. Symptomatic Improvement Within 3 Days With Tofacitinib Induction Therapy in Patients With Ulcerative Colitis: Results From OCTAVE Induction 1 and 2: 609. (October 2017)

Authors:
Hanauer, Stephen; Panaccione, Remo; Danese, Silvio; Cheifetz, Adam; Reinisch, Walter; Higgins, Peter D.R.; Woodworth, Deborah A.; Zhang, Haiying; Friedman, Gary S.; Lawendy, Nervin; Quirk, Daniel; Nduaka, Chudy I.; Su, Chinyu
Journal:
American journal of gastroenterology
Issue:
Volume 112(2017)Supplement 1
Page Start:
Record Type:
Journal Article
View Content:
Available online (eLD content is only available in our Reading Rooms) ↗

5. Tofacitinib for Maintenance Therapy in Patients With Active Ulcerative Colitis in the Phase 3 OCTAVE Sustain Trial: Results by Local and Central Endoscopic Assessments: 607. (October 2017)

Authors:
Feagan, Brian G.; Vermeire, Séverine; Sandborn, William J.; Reinisch, Walter; Panés, Julian; Tarabar, Dino; Su, Chinyu; Niezychowski, Wojciech; Zhang, Haiying; Friedman, Gary S.; Woodworth, Deborah A.; Sands, Bruce E.
Journal:
American journal of gastroenterology
Issue:
Volume 112(2017)Supplement 1
Page Start:
Record Type:
Journal Article
View Content:
Available online (eLD content is only available in our Reading Rooms) ↗

6. Tofacitinib, an Oral Janus Kinase Inhibitor, in the Treatment of Ulcerative Colitis: Open‐Label, Long‐term Extension Study: 714. (October 2017)

Authors:
Lichtenstein, Gary R.; Loftus, Edward V.; Bloom, Stuart; Lawendy, Nervin; Friedman, Gary S.; Zhang, Haiying; Wang, Wenjin; Thorpe, Andrew J.; Nduaka, Chudy I.; Su, Chinyu
Journal:
American journal of gastroenterology
Issue:
Volume 112(2017)Supplement 1
Page Start:
Record Type:
Journal Article
View Content:
Available online (eLD content is only available in our Reading Rooms) ↗

7. Use of biomarkers to improve immunosuppressive drug development and outcomes in renal organ transplantation: A meeting report. Issue 6 (17th March 2020)

Authors:
Mannon, Roslyn B.; Morris, Randall E.; Abecassis, Michael; Axelrod, David; Bala, Shukal; Friedman, Gary S.; Heeger, Peter S.; Lentine, Krista L.; Loupy, Alexandre; Murphy, Barbara; Nickerson, Peter; Sarwal, Minnie; O'Doherty, Inish; Spear, Nicole; Karpen, Stephen R.
Journal:
American journal of transplantation
Issue:
Volume 20:Issue 6(2020)
Page Start:
1495
Record Type:
Journal Article
View Content:
Available online (eLD content is only available in our Reading Rooms) ↗